Among the search engine hits will be a press release from the company and a multitude of news commentaries and blogposts, all various incarnations of the press release itself. These sources will have a summary of the best results from the Phase 3 clinical trial, promising (maybe self-congratulatory) statements from the CEO or CMO of the company, a paragraph on safety signals and usual disclaimers.
But what if you actually want to know more about the drug target, its biology, chemistry, structural biology, pharmacology, bioactivity (and experimental models) and all kinds of apparently boring (to the investment community) scientific data.
This "mundane" data is generally scattered in journal articles, conferences abstracts and posters, and patent filings. Now there is an easier way to get a snapshot of this data: via a public database canSAR.
